Pentwater Capital Management’s Evolent Health EVH Stock Holding History

Pentwater Capital Management’s Portfolio EVH Stock Details EVH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-20,000	Closed	-$568K	–	149
2018 Q3	$568K	Sell	20,000 -10,000	-33%	-$239K	﹤0.01%	124
2018 Q2	$632K	Buy	+30,000	New	+$568K	﹤0.01%	104

Other funds holding EVH

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Pentwater Capital Management's EVH Position: Q4 2018 in Review

Pentwater Capital Management sold out of Evolent Health (EVH) in Q4 2018, closing a stake of 20,000 shares — an estimated $568K sold.

Pentwater Capital Management first reported a position in EVH in Q2 2018 and held it in 2 quarters. The position peaked at $632K in Q2 2018. 186 funds tracked by Wall St. Rank hold EVH as of Q4 2018.

Pentwater Capital Management reported no remaining Evolent Health position as of Q4 2018 after selling out during the quarter.
Pentwater Capital Management sold 20,000 Evolent Health shares in Q4 2018, an estimated $568K.
Pentwater Capital Management first reported a position in Evolent Health in Q2 2018 and held it in 2 quarters.
Pentwater Capital Management's Evolent Health position peaked at $632K in Q2 2018.
186 funds tracked by Wall St. Rank held Evolent Health as of Q4 2018.

Based on Pentwater Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.